Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer.
Bozionellou V, Mavroudis D, Perraki M, Papadopoulos S, Apostolaki S, Stathopoulos E, Stathopoulou A, Lianidou E, Georgoulias V. Bozionellou V, et al. Clin Cancer Res. 2004 Dec 15;10(24):8185-94. doi: 10.1158/1078-0432.CCR-03-0094. Clin Cancer Res. 2004. PMID: 15623593
Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients.
Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A, Kalbakis K, Androulakis N, Kouroussis C, Pallis T, Christophylakis C, Argyraki K, Lianidou ES, Stathopoulos S, Georgoulias V, Mavroudis D. Xenidis N, et al. Among authors: lianidou es. J Clin Oncol. 2006 Aug 10;24(23):3756-62. doi: 10.1200/JCO.2005.04.5948. Epub 2006 Jun 12. J Clin Oncol. 2006. PMID: 16769987
HER-2 DNA quantification of paraffin-embedded breast carcinomas with LightCycler real-time PCR in comparison to immunohistochemistry and chromogenic in situ hybridization.
Ntoulia M, Kaklamanis L, Valavanis C, Kafousi M, Stathopoulos E, Arapantoni P, Mavroudis D, Georgoulias V, Lianidou ES. Ntoulia M, et al. Among authors: lianidou es. Clin Biochem. 2006 Sep;39(9):942-6. doi: 10.1016/j.clinbiochem.2006.06.001. Epub 2006 Jul 13. Clin Biochem. 2006. PMID: 16916505
Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G, Sotiriou C, Georgoulias V, Mavroudis D. Ignatiadis M, et al. J Clin Oncol. 2007 Nov 20;25(33):5194-202. doi: 10.1200/JCO.2007.11.7762. Epub 2007 Oct 22. J Clin Oncol. 2007. PMID: 17954712
Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer.
Ignatiadis M, Perraki M, Apostolaki S, Politaki E, Xenidis N, Kafousi M, Stathopoulos E, Lianidou E, Sotiriou C, Georgoulias V, Mavroudis D. Ignatiadis M, et al. Clin Breast Cancer. 2007 Dec;7(11):883-9. doi: 10.3816/CBC.2007.n.054. Clin Breast Cancer. 2007. PMID: 18269779
Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer.
Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M, Chlouverakis G, Stathopoulos E, Lianidou E, Georgoulias V, Mavroudis D. Ignatiadis M, et al. Clin Cancer Res. 2008 May 1;14(9):2593-600. doi: 10.1158/1078-0432.CCR-07-4758. Clin Cancer Res. 2008. PMID: 18451221
161 results